vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Richmond Mutual Bancorporation, Inc. (RMBI). Click either name above to swap in a different company.
Richmond Mutual Bancorporation, Inc. is the larger business by last-quarter revenue ($13.1M vs $9.2M, roughly 1.4× Foghorn Therapeutics Inc.). Richmond Mutual Bancorporation, Inc. runs the higher net margin — 26.1% vs -234.3%, a 260.4% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 18.1%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 9.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
FHTX vs RMBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $13.1M |
| Net Profit | $-21.7M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -258.2% | — |
| Net Margin | -234.3% | 26.1% |
| Revenue YoY | 223.8% | 18.1% |
| Net Profit YoY | -11.1% | 37.7% |
| EPS (diluted) | $-0.35 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $13.1M | ||
| Q3 25 | $8.2M | $12.6M | ||
| Q2 25 | $7.6M | $11.8M | ||
| Q1 25 | $6.0M | $11.4M | ||
| Q4 24 | $2.9M | $11.1M | ||
| Q3 24 | $7.8M | $10.8M | ||
| Q2 24 | $6.9M | $10.7M | ||
| Q1 24 | $5.0M | $11.0M |
| Q4 25 | $-21.7M | $3.4M | ||
| Q3 25 | $-15.8M | $3.6M | ||
| Q2 25 | $-17.9M | $2.6M | ||
| Q1 25 | $-18.8M | $2.0M | ||
| Q4 24 | $-19.5M | $2.5M | ||
| Q3 24 | $-19.1M | $2.5M | ||
| Q2 24 | $-23.0M | $2.1M | ||
| Q1 24 | $-25.0M | $2.4M |
| Q4 25 | -258.2% | — | ||
| Q3 25 | -226.9% | — | ||
| Q2 25 | -279.2% | — | ||
| Q1 25 | -385.0% | — | ||
| Q4 24 | -840.5% | — | ||
| Q3 24 | -305.5% | — | ||
| Q2 24 | -386.6% | — | ||
| Q1 24 | -558.3% | — |
| Q4 25 | -234.3% | 26.1% | ||
| Q3 25 | -194.4% | 28.6% | ||
| Q2 25 | -237.3% | 22.0% | ||
| Q1 25 | -316.4% | 17.2% | ||
| Q4 24 | -682.9% | 22.4% | ||
| Q3 24 | -244.9% | 23.0% | ||
| Q2 24 | -333.6% | 19.3% | ||
| Q1 24 | -495.4% | 21.6% |
| Q4 25 | $-0.35 | $0.35 | ||
| Q3 25 | $-0.25 | $0.36 | ||
| Q2 25 | $-0.28 | $0.26 | ||
| Q1 25 | $-0.30 | $0.20 | ||
| Q4 24 | $-0.23 | $0.25 | ||
| Q3 24 | $-0.31 | $0.24 | ||
| Q2 24 | $-0.45 | $0.20 | ||
| Q1 24 | $-0.59 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $145.8M |
| Total Assets | $198.1M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $33.1M | ||
| Q3 25 | $89.3M | $34.3M | ||
| Q2 25 | $72.6M | $27.2M | ||
| Q1 25 | $61.0M | $27.0M | ||
| Q4 24 | $55.5M | $21.8M | ||
| Q3 24 | $57.7M | $19.6M | ||
| Q2 24 | $138.9M | $19.0M | ||
| Q1 24 | $79.3M | $20.3M |
| Q4 25 | $-108.5M | $145.8M | ||
| Q3 25 | $-89.7M | $140.0M | ||
| Q2 25 | $-76.7M | $132.3M | ||
| Q1 25 | $-61.7M | $130.9M | ||
| Q4 24 | $-45.5M | $132.9M | ||
| Q3 24 | $-28.3M | $140.0M | ||
| Q2 24 | $-14.3M | $131.1M | ||
| Q1 24 | $-97.5M | $132.4M |
| Q4 25 | $198.1M | $1.5B | ||
| Q3 25 | $205.0M | $1.5B | ||
| Q2 25 | $226.2M | $1.5B | ||
| Q1 25 | $258.7M | $1.5B | ||
| Q4 24 | $284.0M | $1.5B | ||
| Q3 24 | $308.4M | $1.5B | ||
| Q2 24 | $328.6M | $1.5B | ||
| Q1 24 | $255.0M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $16.0M |
| Free Cash FlowOCF − Capex | — | $14.6M |
| FCF MarginFCF / Revenue | — | 111.9% |
| Capex IntensityCapex / Revenue | 0.0% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 4.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | $26.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $16.0M | ||
| Q3 25 | $-18.9M | $6.3M | ||
| Q2 25 | $-21.0M | $4.8M | ||
| Q1 25 | $-24.0M | $2.2M | ||
| Q4 24 | $-24.5M | $14.8M | ||
| Q3 24 | $-21.0M | $2.9M | ||
| Q2 24 | $-25.5M | $2.9M | ||
| Q1 24 | $-29.3M | $2.2M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | $-21.0M | $4.2M | ||
| Q1 25 | $-24.0M | $2.1M | ||
| Q4 24 | $-25.0M | $14.3M | ||
| Q3 24 | $-21.3M | $2.8M | ||
| Q2 24 | $-25.6M | $2.8M | ||
| Q1 24 | $-29.4M | $2.0M |
| Q4 25 | — | 111.9% | ||
| Q3 25 | — | 46.2% | ||
| Q2 25 | -278.2% | 35.6% | ||
| Q1 25 | -403.2% | 18.4% | ||
| Q4 24 | -875.3% | 129.3% | ||
| Q3 24 | -273.0% | 25.7% | ||
| Q2 24 | -371.0% | 26.2% | ||
| Q1 24 | -583.1% | 18.7% |
| Q4 25 | 0.0% | 10.4% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.3% | 5.3% | ||
| Q1 25 | 0.5% | 0.7% | ||
| Q4 24 | 16.8% | 4.2% | ||
| Q3 24 | 4.0% | 1.1% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 2.0% | 1.1% |
| Q4 25 | — | 4.68× | ||
| Q3 25 | — | 1.75× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 5.96× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
